CWA Asset Management Group LLC Reduces Stake in Johnson & Johnson (NYSE:JNJ)

CWA Asset Management Group LLC cut its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 0.3% during the fourth quarter, Holdings reports. The firm owned 182,287 shares of the company’s stock after selling 499 shares during the period. Johnson & Johnson makes up 2.6% of CWA Asset Management Group LLC’s holdings, making the stock its 6th biggest holding. CWA Asset Management Group LLC’s holdings in Johnson & Johnson were worth $32,201,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. TD Capital Management LLC acquired a new stake in Johnson & Johnson in the third quarter worth about $48,000. Cowa LLC purchased a new position in shares of Johnson & Johnson in the 3rd quarter valued at approximately $58,000. Legend Financial Advisors Inc. purchased a new stake in Johnson & Johnson during the 3rd quarter worth approximately $59,000. Adirondack Retirement Specialists Inc. acquired a new position in Johnson & Johnson during the 3rd quarter valued at approximately $67,000. Finally, Heritage Wealth Management LLC purchased a new position in Johnson & Johnson in the 2nd quarter worth $84,000. 67.94% of the stock is currently owned by institutional investors.

Insider Transactions at Johnson & Johnson

In related news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the sale, the insider now owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.35% of the company’s stock.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $152.38 on Friday. Johnson & Johnson has a 52-week low of $150.71 and a 52-week high of $186.69. The firm has a market capitalization of $396.84 billion, a price-to-earnings ratio of 22.61, a PEG ratio of 2.65 and a beta of 0.54. The company has a fifty day simple moving average of $161.97 and a 200-day simple moving average of $167.88. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35.

Johnson & Johnson (NYSE:JNJGet Rating) last released its earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.22 by $0.13. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The business had revenue of $23.71 billion during the quarter, compared to analyst estimates of $23.90 billion. During the same quarter in the prior year, the firm earned $2.13 earnings per share. The company’s revenue for the quarter was down 4.4% compared to the same quarter last year. On average, equities analysts anticipate that Johnson & Johnson will post 10.5 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st were issued a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.97%. The ex-dividend date of this dividend was Friday, February 17th. Johnson & Johnson’s payout ratio is 67.06%.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. started coverage on shares of Johnson & Johnson in a research report on Thursday. They set a “strong-buy” rating for the company. Citigroup boosted their price objective on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a report on Monday, December 12th. Atlantic Securities raised their target price on Johnson & Johnson from $160.00 to $168.00 and gave the stock a “neutral” rating in a report on Wednesday, January 25th. Guggenheim assumed coverage on Johnson & Johnson in a report on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price target for the company. Finally, Piper Sandler dropped their price objective on shares of Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $174.73.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.

Recommended Stories

Want to see what other hedge funds are holding JNJ? Visit to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with's FREE daily email newsletter.